IndiaTuberculosis profile
Population  2014 1 295 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 220 (150–350) 17 (12–27)
Mortality (HIV+TB only) 31 (25–38) 2.4 (2–2.9)
Prevalence  (includes HIV+TB) 2 500 (1 700–3 500) 195 (131–271)
Incidence  (includes HIV+TB) 2 200 (2 000–2 300) 167 (156–179)
Incidence (HIV+TB only) 110 (96–120) 8.3 (7.4–9.3)
         
Case detection, all forms (%) 74 (70–80)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 2.2 (1.9–2.6) 15 (11–19)
MDR-TB cases among notified pulmonary
TB cases
24 000 (21 000–29 000) 47 000 (35 000–59 000)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 754 268   124 679
Pulmonary, clinically diagnosed 343 032   112 066
Extrapulmonary 275 502    
       
Total new and relapse 1 609 547    
Previously treated, excluding relapses 74 368    
Total cases notified 1 683 915    
Among 1 609 547 new and relapse cases:
95 709 (6%) cases aged under 15 years; male:female ratio: 1.9
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 12 795 (2%) 214 209 (69%) 255 897
Laboratory-confirmed RR-/MDR-TB cases     25 748
Patients started on MDR-TB treatment ***     24 073
TB/HIV 2014 Number (%)
TB patients with known HIV status 1 034 712 (61)
HIV-positive TB patients 44 171 (4)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 41 066 (93)
HIV-positive TB patients on antiretroviral therapy (ART) 39 800 (90)
HIV-positive people screened for TB 1 114 394  
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (88) 1 243 905
Previously treated cases, excluding relapse, registered in 2013 (66) 171 712
HIV-positive TB cases, all types, registered in 2013 (76) 44 027
RR-/MDR-TB cases started on second-line treatment in 2012 (46) 14 051
XDR-TB cases started on second-line treatment in 2012 (32) 129
Laboratories 2014  
Smear (per 100 000 population) 1.0
Culture (per 5 million population) 0.3
Drug susceptibility testing (per 5 million population) 0.2
Sites performing Xpert MTB/RIF 121
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2015  
National TB programme budget (US$ millions) 261
% Funded domestically 46%
% Funded internationally 54%
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-05-26 Data: www.who.int/tb/data